Adult-onset Still's disease following mRNA COVID-19 vaccination

Sharabi, Amir; Shiber, Shachaf; Molad, Yair

doi:10.1016/j.clim.2021.108878

Cited by 30 publications

(38 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Details of the clinical features, laboratory findings, and treatment outcomes of the previously reported 10 cases [ 7 , 8 , 9 , 10 , 11 , 12 , 13 ] and this present one are shown in Table 1 . The patient in this case report had received two doses of Sinovac followed by one of viral vector ChAdOx1 (AstraZeneca]) vaccine, which caused the onset of AOSD-like syndrome, whereas five of the other patients developed AOSD-like syndrome after the first dose of ChAdOx1 (AstraZeneca).…”

Section: Review Of the Literaturementioning

confidence: 91%

See 1 more Smart Citation

Adult-Onset Still’s Disease-like Syndrome following COVID-19 Vaccination: A Case Report and Review of the Literature

et al. 2022

View full text Add to dashboard Cite

Adult-onset Still’s disease (AOSD)-like syndrome has rarely been reported as a complication of COVID-19 vaccination. This study reports a 31-year-old female patient who presented with fever, myalgia, arthralgia, pleuropericarditis, leukocytosis, and transaminitis following ChAdOx1 vaccination, and met Yamaguchi’s criteria. A PubMed literature search, performed up until March 2022, identified 10 such cases. A total of 11 cases, including the one in this report, developed AOSD-like syndrome after administration of the viral vector (ChAdOx1) vaccine (six patients) and mRNA vaccine (five patients: BNT162b2 in four and mRNA-1273 in one). There were four male and seven female patients, with their median (Q1, Q3) age and the onset of symptoms after vaccination being 36 years (29, 45) and 10 days (6, 13), respectively. Fever (100%), arthralgia/arthritis (90.9%), skin rashes (81.8%), and sore throat (81.8%) were the main clinical findings. Pericarditis (45.5%), myocarditis/cardiac dysfunction (36.4%), pleuritis (54.6%), and pulmonary infiltrations (36.4%) were also common. One patient developed macrophage activation syndrome. One patient responded well to non-steroidal anti-inflammatory drugs, and the other six showed a good response to high-dose corticosteroids alone. Of the remaining four patients, who showed partial responses to high dose corticosteroids, showed good responses to biological agents. AOSD-like syndrome following COVID-19 vaccination shared many similar clinical features and treatment outcomes to those of idiopathic AOSD (but with a higher prevalence of cardiopulmonary involvement in the former). Physicians should be aware of this extremely rare complication to achieve early diagnosis and provide proper management.

show abstract

Section: Review Of the Literaturementioning

confidence: 91%

“…Of these autoimmune syndromes, AOSD-like syndrome has rarely been described. It is interesting that a PubMed literature search, performed up until March 2022, identified seven articles (10 cases) of AOSD-like syndrome following COVID-19 vaccination [ 7 , 8 , 9 , 10 , 11 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Adult-Onset Still’s Disease-like Syndrome following COVID-19 Vaccination: A Case Report and Review of the Literature

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that host genetic factors increase susceptibility to COVID-19 infection and severity, including genetic association with HLA, ACE and ABO A positive group. By genome wide association study(GWAS), certain chromosomes [ 3 , 9 , 12 , 19 ] have been linked to COVID-19 infection [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…These patients have highly activated innate immune cells, lack naive T and B cells and show elevated expression of type I IFN (IFN-β) and type III IFN (IFN-λ1) that remained persistently high at 8 months after infection [ 10 ]. With a wide use of COVID-19 vaccines, several cases of COVID-19 vaccination-induced autoinflammatory disease have been reported [ [11] , [12] , [13] ]. These patients were clinically classified as having adult onset Still disease without undergoing genetic testing for periodic fever syndromes.…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2/COVID-19 and its relationship with NOD2 and ubiquitination

Rivera

Patnaik

Salvemini

et al. 2022

Clinical Immunology

View full text Add to dashboard Cite

“…Various coronavirus disease 2019 (COVID- 19) vaccines have been developed at a remarkably accelerated pace, with more than nine vaccines already having official approval for use around the world [1,2]. These primarily include mRNA vaccines (Pfizer, Moderna), adenoviral vector vaccines (AstraZeneca, Johnson Pharma), and inactivated whole-virus vaccines (Sinopharm, Sinovac) [3].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Vaccine-Related Arthritis: A Descriptive Study of Case Reports on a Rare Complication

Dawoud¹,

Haddad²,

Shah³

et al. 2022

Cureus

View full text Add to dashboard Cite

Large-scale coronavirus disease 2019 (COVID-19) vaccination programs have been rolled out worldwide. Vaccines that are widely used globally include mRNA vaccines, adenoviral vector vaccines, and inactivated whole-virus vaccines. COVID-19 vaccines can lead to varying side effects. Among the most common of these adverse effects are pain at the injection site, fatigue, and headaches. Some side effects, however, are not very well documented, and these include joint-related adverse effects. In this review, we assess the epidemiology and clinical features of post-COVID-19 vaccination joint-related adverse effects based on the analysis of 16 patient case reports.Based on our analysis, we found that females formed the majority of the cases, accounting for 62.5% of patients, while 37.5% of the cases were males. The mean age of presentation among the patients was 54.8 years, with a standard deviation (SD) of 17.49 years. In 37.5% of the cases, patients received the Sinovac vaccine. The proportion of patients who received other vaccines was as follows: the Pfizer vaccine: 31.25%; Sputnik V: 12.5%; Moderna, AstraZeneca, and Covaxin: 6.25% each.The characteristics of joint-related adverse effects following COVID-19 vaccination were analyzed in this study. We identified several key findings related to factors such as age, gender, type of vaccine, clinical features, and diagnosis modality. Our analysis showed that more cases were reported among individuals who received the Sinovac vaccine, as compared to the others. Further research is required to examine the underlying cause of this association.

show abstract

Adult-onset Still's disease following mRNA COVID-19 vaccination

Cited by 30 publications

References 6 publications

Adult-Onset Still’s Disease-like Syndrome following COVID-19 Vaccination: A Case Report and Review of the Literature

Adult-Onset Still’s Disease-like Syndrome following COVID-19 Vaccination: A Case Report and Review of the Literature

SARS-CoV-2/COVID-19 and its relationship with NOD2 and ubiquitination

COVID-19 Vaccine-Related Arthritis: A Descriptive Study of Case Reports on a Rare Complication

Contact Info

Product

Resources

About